WAVE Life Sciences Ltd (FRA:1U5)
€ 12.8 -0.1 (-0.78%) Market Cap: 1.89 Bil Enterprise Value: 1.62 Bil PE Ratio: 0 PB Ratio: 13.52 GF Score: 41/100

WAVE Life Sciences Ltd FOCUS-C9 Clinical Trial Results Conference Call Transcript

May 23, 2023 / 12:30PM GMT
Operator

Good day, and thank you for standing by. Welcome to the Wave Life Sciences conference call. (Operator Instructions)

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Kate Rausch, Vice President of Corporate Affairs and Investor Relations at Wave Life Sciences. Please go ahead.

Kate Rausch
Wave Life Sciences Ltd. - Head of IR

Thank you, operator. This morning, we issued a news release announcing top line data from our FOCUS-C9 clinical trial. A replay of this webcast will be available on the website, www.wavelifesciences.com following today's call.

Before we begin, I'd like to remind you that discussions during this conference call will include forward-looking statements. These statements are subject to a number of risks and uncertainties that could cause our actual results to differ materially from those described in these forward-looking statements. The factors that could cause

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot